1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nosa Plugs AB

Nosa Plugs AB

NOSA.ST
Nosa Plugs ABSE flagStockholm Stock Exchange
0.52
SEK
-NaN
- -
133.99MMarket Cap
Nosa Plugs AB
NOSA.ST
(Stockholm Stock Exchange)

Recent

price

0.52

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.01
0.26
0.08
0.04
0.12
0.06
0.07
0.08
0.1
0.11
Revenue per Share
-2
-1.22
-1.43
-2.09
-2.98
-7.22
-1.23
-0.16
-0.29
-0.05
-0.03
-0.03
Basic EPS, GAAP
-5.96
-1.95
-2.52
-2.52
-2.94
-2.49
-0.35
-0.06
-0.11
-0.07
-0.03
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.76
-1.51
-2.72
-4.45
-6.58
-12.33
-9.52
-0.39
-0.52
-0.44
-0.42
-0.4
Book Value per Share
18.24
3.33
3.19
2.85
1.85
2.54
0.51
0.05
0.16
0.07
0.04
0.03
Tangible Book Value per Share
3
15
17
20
25
32
48
112
160
210
237
249
Basic Weighted Avg Shares
- -
- -
- -
5
2
1
6
7
10
16
24
28
Sales/Revenue/Turnover
- -
- -
-13,188.71
-880.65
-3,795.25
-7,576.44
-110.35
-201.97
-136.18
-64.29
-33.6
-32.37
Operating Margin (%)
- -
- -
3
8
24
29
20
6
1
2
4
5
Depreciation Expense
-5
-18
-25
-42
-74
-229
-59
-18
-47
-10
-8
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-10,037.9
-799.52
-3,810.07
-16,760.42
-1,000.43
-260.18
-447.94
-63.1
-33.63
-30.51
Profit Margin (%)
33
39
39
35
20
77
10
4
3
9
14
13
Working Capital
- -
- -
- -
- -
3
- -
6
1
1
- -
- -
1
LT Debt
151
168
192
200
188
102
39
7
27
17
41
39
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
260
260
260
Market Capitalization
157
144
131

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
29
28
27
Cash, Cash Equivalents & STI
19
17
17
Accounts Receivable, Net
3
4
5
Inventories
5
5
4
Total Current Liabilities
12
13
13
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.28%
52.95%
148.02%
Free Cash Flow
15.81%
-10.8%
-56.49%
Net Income, GAAP
57.02%
-16.36%
-20.84%
Sales/Revenue/Turnover
- -
100.07%
48.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
4
4
5
16
2025
4
5
4
11
24
2026
8
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
-0.01
-0.01
-0.05
2025
-0.01
-0.01
-0.02
- -
-0.03
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Guangdong True Health Medical Technology Development Co., Ltd. (2697.HK)
Bio-Rad Laboratories, Inc. (BIO-B)
Vivani Medical, Inc. (VANI)
Surmodics, Inc. (SRDX)
Delta Asia International Corporation (6762.TWO)
Senzime AB (publ) (SEZI.ST)
Business
Nosa Plugs AB (publ) (NOSA.ST), a Sweden-based medical technology company founded in 2014 and headquartered in Stockholm, develops, manufactures and sells innovative intranasal breathing products designed to improve quality of life by addressing issues related to the respiratory and olfactory systems, including bad odors, allergies, infections and smell disorders; its core patented product portfolio comprises NOSA odor control plugs with menthol fragrance for discreet intranasal odor protection used by healthcare professionals, police, ambulance and firefighters; NOSA allergy filters that capture PM10 airborne particles such as pollen, pet dander, dust and mold; NOSA microbial control plugs that reduce viruses and bacteria in inhaled air; clinically proven NOSA smell training kits with scented inserts and interactive app for olfactory recovery in cases of hyposmia and parosmia; and NOSA Nozoil sesame oil-based nasal spray for dry mucous membranes and itching, following distribution agreements and the June 2025 announcement of intent to acquire PharmaCure Health Care International AB for SEK 27.2 million on a debt- and cash-free basis pending financing via up to SEK 30 million directed share issue and regulatory approvals. The company operates in B2B and B2C segments targeting consumers, healthcare providers and emergency services across Sweden (31.5% of FY2024 sales), Germany/DACH region (23%), United States, Australia, Denmark, United Kingdom, Norway, Switzerland, Benelux and France, with subsidiaries NoseOption AB and NoseOption Inc. since March 2023 reverse merger listing on Nasdaq First North Stockholm (previously Frisq Holding AB); recent developments include Q2 2025 distributor agreements with Norengros AS in Norway and German/Austrian markets, October 2025 partnership with Apotera AS for Nordic pharmacy launch strengthening consumer presence post-PharmaCure intent, strong FY2024 revenue growth of 55% to SEK 16.1 million driven by odor control, intensified DACH marketing and Nozoil rollout, new strategic goals for 50% average annual growth through 2026, EBITDA positivity by Q4 2025, ENT acquisitions, drug delivery partnerships and 15%+ margins by 2026, alongside production capacity expansion by 140% and positive cash flow achievement in April 2025.